Panntherapi develops innovative drugs in Neurology by acting on a specific target, the activated pannexin 1 channel, aiming a better efficacy and tolerance than current drugs.
Panntherapi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases:
- Innovative target addressing the root cause of the diseases
- Representative non-clinical model using among others ex vivo human brain tissues
Company Details
- Employees
- 11
- Founded
- -
- Address
- 10 Rue Descartes, Nîmes,30000,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.panntherapi.com
- Keywords
- Biotech, Neurology, Epilepsy, Deeptech.
- HQ
- Nîmes
Panntherapi Questions
Panntherapi's website is http://www.panntherapi.com
Panntherapi's LinkedIn profile is https://fr.linkedin.com/company/panntherapi
Panntherapi has
11 employees.
View email and phone details for 11
employees at Panntherapi.
Panntherapi's industry is
Pharmaceutical Manufacturing
Panntherapi's top competitors are
Recobia Therapeutics,
Pep-Therapy,
Weezion,
Peptitech,
Elikya Therapeutics,
Biomunex Pharmaceuticals,
Byorna,
Avec Brillaud Consulting,
Cure51,
Averoa.
Panntherapi's categories are Pharmaceutical Manufacturing
Panntherapi's founding year is 2021
